Garrigues advises Vivebiotech on €3.5m capital increase
Garrigues advised San Sebastian-based biotechnology company Vivebiotech on a €3.5 million capital increase.
Vivebiotech is the only biotechnology company in Spain that produces lentiviral vectors for tests on rare diseases and hematological cancer.
The capital was raised from Easo Ventures, the Inveready venture capital fund, the Basque public company Dpri, Fundación Kutxa, and entrepreneurs from Euskadi.
The company will use the capital increase to multiply its production capacity by 30 per cent and increase its current workforce by 25 per cent.
A Garrigues team based in the firm’s San Sebastian office – including partner Carla Frangoni (pictured) and associate Gorka Esnal – advised on the deal.